Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 6/20 | 0.60 |
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491161 | 1.00 | CACNA1B (0.60) | CACNA1BCTSSCTSKAAK1ALDH1A1 | |
| SCHEMBL490917 | 1.00 | CACNA1B (0.60) | CACNA1BCTSSCTSKAAK1ALDH1A1 | |
| SCHEMBL12333300 | 0.92 | CACNA1B (0.50) | CACNA1BCTSSCTSKAAK1ALDH1A1 | |
| SCHEMBL12332970 | 0.92 | CACNA1B (0.50) | CACNA1BCTSSCTSKAAK1ALDH1A1 | |
| SCHEMBL12332971 | 0.91 | CACNA1B (0.49) | CACNA1BCTSSCTSKAAK1ALDH1A1 | |
| SCHEMBL1147980 | 0.89 | CACNA1B (0.53) | CACNA1BCTSSCTSKAAK1ALDH1A1 | |
| SCHEMBL1147982 | 0.89 | CACNA1B (0.53) | CACNA1BCTSSCTSKAAK1ALDH1A1 | |
| SCHEMBL13897570 | 0.85 | CTSK (0.50) | CACNA1BCTSSCTSKAAK1ALDH1A1 | |
| SCHEMBL490471 | 0.84 | CACNA1B (0.44) | CACNA1BCTSSCTSKAAK1PPARG | |
| SCHEMBL490387 | 0.84 | CACNA1B (0.44) | CACNA1BCTSSCTSKAAK1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106091-B2 | Inhibitors of IKK-beta serine-threonine protein kinase | CHROMA THERAPEUTICS LTD. (GB) | 2012-01-31 | — | — | US | disclosed |
| EP-2086956-B1 | INHIBITORS OF IKK- BETA SERINE-THREONINE PROTEIN KINASE | CHROMA THERAPEUTICS LTD (GB) | 2011-09-14 | — | — | EP | disclosed |
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | CHROMA THERAPEUTICS LTD. (GB) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069473-A1 | Inhibitors Of IKK-Beta Serine-Threonine Protein Kinase | IKBKB, IKBKE, CHUK | CACNA1B 2344/4885CTSS 2844/4885CTSK 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.